53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

Publication | Closed Access

DOI

Citations

References

2006

Year

Roy S. Herbst, Vince O’Neill, Louis Fehrenbacher, Chandra P. Belani, P. Bonomi, L. Hart, O.O. Melnyk, Alan Sandler, MC Lin, J. Bloss

European Journal of Cancer Supplements

MedicinePharmacologyClinical TrialsErlotinib HydrochlorideImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyLung Cancer